ICAD: iCAD, Inc. Price/Earnings to Growth Multiple

Symbol and logo of brand iCAD Corp (ICAD)

iCAD, Inc. (ICAD) revenues rely on insurance reimbursements and the digitalization of radiology. This PEG chart, provided by the GURU.Markets system for analysis, serves as a confidence indicator, where 0.00 indicates the current valuation level. The company leads in the development of AI algorithms for radiation therapy, growing SaaS revenue by integrating software into the equipment of leading CT scanner manufacturers.

Price/Earnings to Growth Ratio: iCAD Inc. (ICAD) for 07/04/2022 - 08/02/2025
Mass-produced product of iCAD Inc.

By analyzing the upward trend of the P/E ratio, one can assess the scaling efficiency of iCAD, Inc. (ICAD) SaaS platforms for early cancer detection in the context of market value. This metric correlates the current earnings multiple with the growth rate of those earnings, where a value below one signals that the asset is undervalued, allowing the investor to strip out one-time write-offs and verify the business's actual expansion potential.

Competing companies

ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|PEG Multiple DCTH|Growth-Adjusted Market Cap to Net Income ymabs.com|PEG Multiple AURA (Aura Biosciences)|CADL - Price/Earnings to Growth Multiple|Accuray Inc. - PEG Multiple|SLS - PEG Multiple|ACTU: PEG Multiple|Growth-Adjusted P/E Ratio CTOR|Price/Earnings to Growth Multiple HURA|TARA: Growth-Adjusted Payback Ratio|PEG Multiple FATE|Growth-Adjusted Market Cap to Net Income aadibio.com|Price/Earnings to Growth Ratio TScan Therapeutics, Inc. TCRX|CSBR: Growth-Adjusted P/E Ratio|XBiotech USA - PEG Multiple|CEL-SCI Corporation (CVM) - Price/Earnings to Growth Multiple|OSTX (OS Therapies Inc) - Price/Earnings to Growth Multiple|RADX - Growth-Adjusted Market Cap to Net Income|ARTV (Artiva Biotherapeutics Inc.) - PEG Multiple|Adlai Nortye Limited (ANL) - Growth-Adjusted Market Cap to Net Income|PEG Multiple VERU|Price/Earnings to Growth Multiple Tempest Therapeutics Inc TPST|PEG Multiple XLO (Xilio Therapeutics)|PEG Multiple Renovaro Biosciences RENB|Mural Bio - PEG Multiple|KAPA (Kairos Pharma Ltd) - Growth-Adjusted P/E Ratio|OKUR: PEG Multiple|Price/Earnings to Growth Multiple CytoMed Therapeutics Limited|CRIS (Curis Inc.) - PEG Multiple|PEG Multiple Apollomics Corp|Price/Earnings to Growth Ratio Tharimmune, Inc. (THAR)|advanbiomed.com - Growth-Adjusted P/E Ratio|PEG Multiple GNPX (Genprex)|CLDI - Price/Earnings to Growth Multiple|Sunshine Biopharma - PEG Multiple|Price to Earnings Adjusted for Growth Rate Xenetic Biosciences|Salarius Pharmaceuticals (SLRX) - Price/Earnings to Growth Ratio|purple-biotech.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple AONC|BGNE: Growth-Adjusted Payback Ratio|PEG Multiple CKPT|Price/Earnings to Growth Multiple Elevation Oncology Inc. ELEV|Ikena Oncology - Price/Earnings to Growth Multiple|PEG Multiple notablelabs.com NTBL|VIRX - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio MOR (MorphoSys Inc)|NAYA: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ascentage (AAPGV)